Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
November 2021 in “Frontiers in medicine” A patient with both bullous lichen planus and systemic lupus erythematosus showed improvement with treatment.
January 2023 in “Pharmaceutics” AA–TF#15 significantly promotes hair regrowth and could be an effective treatment for androgenic alopecia.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
January 2022 in “Surgical and Cosmetic Dermatology” People with androgenic alopecia (AGA) have a higher chance of getting metabolic syndrome.
January 2022 in “Advances in Clinical Medicine” January 2020 in “Brazilian Journal of Pharmaceutical Sciences” Finasteride worsens heart damage from nandrolone decanoate but protects against cell damage.